Comprehensive Genomic Characterization of Squamous Cell Lung Cancers

Overview

Journal Nature

Specialty Science

Date 2012 Sep 11

PMID 22960745

Citations 2147

Affiliations

Soon will be listed here.

Abstract

Lung squamous cell carcinoma is a common type of lung cancer, causing approximately 400,000 deaths per year worldwide. Genomic alterations in squamous cell lung cancers have not been comprehensively characterized, and no molecularly targeted agents have been specifically developed for its treatment. As part of The Cancer Genome Atlas, here we profile 178 lung squamous cell carcinomas to provide a comprehensive landscape of genomic and epigenomic alterations. We show that the tumour type is characterized by complex genomic alterations, with a mean of 360 exonic mutations, 165 genomic rearrangements, and 323 segments of copy number alteration per tumour. We find statistically recurrent mutations in 11 genes, including mutation of TP53 in nearly all specimens. Previously unreported loss-of-function mutations are seen in the HLA-A class I major histocompatibility gene. Significantly altered pathways included NFE2L2 and KEAP1 in 34%, squamous differentiation genes in 44%, phosphatidylinositol-3-OH kinase pathway genes in 47%, and CDKN2A and RB1 in 72% of tumours. We identified a potential therapeutic target in most tumours, offering new avenues of investigation for the treatment of squamous cell lung cancers.

Citing Articles

Advancements in proteogenomics for preclinical targeted cancer therapy research.

Suo Y, Song Y, Wang Y, Liu Q, Rodriguez H, Zhou H Biophys Rep. 2025; 11(1):56-76.

PMID: 40070661 PMC: 11891078. DOI: 10.52601/bpr.2024.240053.

Microbial metabolites control self-renewal and precancerous progression of human cervical stem cells.

Myeong J, Lee M, Lee B, Kim J, Nam Y, Choi Y Nat Commun. 2025; 16(1):2327.

PMID: 40057497 PMC: 11890575. DOI: 10.1038/s41467-025-57323-6.

KEAP1-NRF2 Interaction in Cancer: Competitive Interactors and Their Role in Carcinogenesis.

Oskomic M, Tomic A, Barbaric L, Matic A, Kindl D, Matovina M Cancers (Basel). 2025; 17(3).

PMID: 39941813 PMC: 11816071. DOI: 10.3390/cancers17030447.

Squamous cell cancers of the aero-upper digestive tract: A unified perspective on biology, genetics, and therapy.

Henick B, Taylor A, Nakagawa H, Wong K, Diehl J, Rustgi A Cancer Cell. 2025; 43(2):178-194.

PMID: 39933897 PMC: 11875029. DOI: 10.1016/j.ccell.2025.01.003.

Multi-omics analyses reveal biological and clinical insights in recurrent stage I non-small cell lung cancer.

Wang C, Li J, Chen J, Wang Z, Zhu G, Song L Nat Commun. 2025; 16(1):1477.

PMID: 39929832 PMC: 11811181. DOI: 10.1038/s41467-024-55068-2.

References

Hammerman P, Sos M, Ramos A, Xu C, Dutt A, Zhou W . Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discov. 2012; 1(1):78-89. PMC: 3274752. DOI: 10.1158/2159-8274.CD-11-0005. View

. Integrated genomic analyses of ovarian carcinoma. Nature. 2011; 474(7353):609-15. PMC: 3163504. DOI: 10.1038/nature10166. View

Singh A, Misra V, Thimmulappa R, Lee H, Ames S, Hoque M . Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer. PLoS Med. 2006; 3(10):e420. PMC: 1584412. DOI: 10.1371/journal.pmed.0030420. View

Kancha R, Peschel C, Duyster J . The epidermal growth factor receptor-L861Q mutation increases kinase activity without leading to enhanced sensitivity toward epidermal growth factor receptor kinase inhibitors. J Thorac Oncol. 2011; 6(2):387-92. DOI: 10.1097/JTO.0b013e3182021f3e. View

Shen R, Olshen A, Ladanyi M . Integrative clustering of multiple genomic data types using a joint latent variable model with application to breast and lung cancer subtype analysis. Bioinformatics. 2009; 25(22):2906-12. PMC: 2800366. DOI: 10.1093/bioinformatics/btp543. View

Paez J, Janne P, Lee J, Tracy S, Greulich H, Gabriel S . EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004; 304(5676):1497-500. DOI: 10.1126/science.1099314. View

Osada H, Tatematsu Y, Yatabe Y, Horio Y, Takahashi T . ASH1 gene is a specific therapeutic target for lung cancers with neuroendocrine features. Cancer Res. 2005; 65(23):10680-5. DOI: 10.1158/0008-5472.CAN-05-1404. View

. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008; 455(7216):1061-8. PMC: 2671642. DOI: 10.1038/nature07385. View

Weiss J, Sos M, Seidel D, Peifer M, Zander T, Heuckmann J . Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med. 2010; 2(62):62ra93. PMC: 3990281. DOI: 10.1126/scitranslmed.3001451. View

10.

Brahmer J, Drake C, Wollner I, Powderly J, Picus J, Sharfman W . Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol. 2010; 28(19):3167-75. PMC: 4834717. DOI: 10.1200/JCO.2009.26.7609. View

11.

Stephens P, McBride D, Lin M, Varela I, Pleasance E, Simpson J . Complex landscapes of somatic rearrangement in human breast cancer genomes. Nature. 2009; 462(7276):1005-10. PMC: 3398135. DOI: 10.1038/nature08645. View

12.

Ju Y, Lee W, Shin J, Lee S, Bleazard T, Won J . A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing. Genome Res. 2011; 22(3):436-45. PMC: 3290779. DOI: 10.1101/gr.133645.111. View

13.

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

14.

Lynch T, Bondarenko I, Luft A, Serwatowski P, Barlesi F, Chacko R . Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J Clin Oncol. 2012; 30(17):2046-54. DOI: 10.1200/JCO.2011.38.4032. View

15.

Govindan R . Summary of the proceedings from the 10th annual meeting of molecularly targeted therapy in non-small cell lung cancer. J Thorac Oncol. 2010; 5(12 Suppl 6):S433. PMC: 3203685. DOI: 10.1097/JTO.0b013e3181fd6fe1. View

16.

Stransky N, Egloff A, Tward A, Kostic A, Cibulskis K, Sivachenko A . The mutational landscape of head and neck squamous cell carcinoma. Science. 2011; 333(6046):1157-60. PMC: 3415217. DOI: 10.1126/science.1208130. View

17.

Mermel C, Schumacher S, Hill B, Meyerson M, Beroukhim R, Getz G . GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol. 2011; 12(4):R41. PMC: 3218867. DOI: 10.1186/gb-2011-12-4-r41. View

18.

Bass A, Lawrence M, Brace L, Ramos A, Drier Y, Cibulskis K . Genomic sequencing of colorectal adenocarcinomas identifies a recurrent VTI1A-TCF7L2 fusion. Nat Genet. 2011; 43(10):964-968. PMC: 3802528. DOI: 10.1038/ng.936. View

19.

Vaske C, Benz S, Sanborn J, Earl D, Szeto C, Zhu J . Inference of patient-specific pathway activities from multi-dimensional cancer genomics data using PARADIGM. Bioinformatics. 2010; 26(12):i237-45. PMC: 2881367. DOI: 10.1093/bioinformatics/btq182. View

20.

Kan Z, Jaiswal B, Stinson J, Janakiraman V, Bhatt D, Stern H . Diverse somatic mutation patterns and pathway alterations in human cancers. Nature. 2010; 466(7308):869-73. DOI: 10.1038/nature09208. View